Trials / Completed
CompletedNCT05162833
Evaluation of the TheraNova Neuromodulation System to Provide Durable Relief of Overactive Bladder Symptoms
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- Theranova, L.L.C. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
To evaluate the safety and durability of the TheraNova Neuromodulation System in overactive bladder (OAB) patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | TheraNova Neuromodulation Device | TENS device |
Timeline
- Start date
- 2022-02-20
- Primary completion
- 2023-12-08
- Completion
- 2023-12-08
- First posted
- 2021-12-17
- Last updated
- 2024-02-28
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT05162833. Inclusion in this directory is not an endorsement.